Vivaldi Capital Management’s UroGen Pharma URGN Stock Holding History

Vivaldi Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,661	Closed	-$282K	–	235
2026 Q1	$282K	Hold	15,661	–	–	0.04%	233
2025 Q4	$367K	Hold	15,661	–	–	0.05%	194
2025 Q3	$312K	Hold	15,661	–	–	0.04%	215
2025 Q2	$215K	Sell	15,661 -4,463	-22%	-$42.8K	0.03%	273
2025 Q1	$223K	Hold	20,124	–	–	0.04%	247
2024 Q4	$211K	Hold	20,124	–	–	0.03%	260
2024 Q3	$256K	Hold	20,124	–	–	0.07%	178
2024 Q2	$338K	Hold	20,124	–	–	0.1%	155
2024 Q1	$256K	Buy	20,124 +3,663	+22%	+$59.9K	0.07%	182
2023 Q4	$309K	Hold	16,461	–	–	0.09%	162
2023 Q3	$231K	Buy	16,461 +4,961	+43%	+$79.6K	0.08%	168
2023 Q2	$119K	Buy	+11,500	New	+$127K	0.04%	195
2021 Q4	–	Sell	-16,650	Closed	-$280K	–	235
2021 Q3	$280K	Buy	+16,650	New	+$264K	0.06%	185
2020 Q4	–	Sell	-10,000	Closed	-$233K	–	327
2020 Q3	$233K	Sell	10,000 -1,000	-9%	-$22.6K	0.05%	221
2020 Q2	$255K	Buy	+11,000	New	+$269K	0.05%	213

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vivaldi Capital Management's URGN Position: Q2 2026 in Review

Vivaldi Capital Management sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 15,661 shares — an estimated $282K sold.

Vivaldi Capital Management first reported a position in URGN in Q2 2020 and held it in 15 quarters. The position peaked at $367K in Q4 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Vivaldi Capital Management reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Vivaldi Capital Management sold 15,661 UroGen Pharma shares in Q2 2026, an estimated $282K.
Vivaldi Capital Management first reported a position in UroGen Pharma in Q2 2020 and held it in 15 quarters.
Vivaldi Capital Management's UroGen Pharma position peaked at $367K in Q4 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Vivaldi Capital Management's 13F filing for Q2 2026.